X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (600) 600
Book Review (144) 144
Newsletter (39) 39
Publication (22) 22
Magazine Article (9) 9
Book Chapter (5) 5
Conference Proceeding (2) 2
Trade Publication Article (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pegaptanib (515) 515
index medicus (400) 400
humans (354) 354
ranibizumab (347) 347
ophthalmology (319) 319
bevacizumab (289) 289
macular degeneration (249) 249
vascular endothelial growth factor a - antagonists & inhibitors (200) 200
female (154) 154
male (153) 153
vascular endothelial growth factor (151) 151
endothelial growth-factor (145) 145
aged (140) 140
age-related macular degeneration (130) 130
angiogenesis inhibitors - therapeutic use (122) 122
pegaptanib sodium (120) 120
macular degeneration - drug therapy (115) 115
antibodies, monoclonal, humanized (107) 107
aptamers, nucleotide - therapeutic use (105) 105
middle aged (105) 105
choroidal neovascularization (101) 101
photodynamic therapy (99) 99
aged, 80 and over (90) 90
intravitreal injections (87) 87
treatment outcome (85) 85
choroidal neovascularization - drug therapy (83) 83
angiogenesis inhibitors - administration & dosage (81) 81
eye diseases (80) 80
verteporfin (77) 77
injections (75) 75
visual acuity (75) 75
vitreous body (75) 75
pharmacology & pharmacy (74) 74
neovascularization (69) 69
angiogenesis inhibitors - adverse effects (66) 66
animals (66) 66
diabetic retinopathy (66) 66
vegf (62) 62
antibodies, monoclonal - therapeutic use (60) 60
injection (60) 60
tomography, optical coherence (59) 59
fluorescein angiography (58) 58
retrospective studies (58) 58
physiological aspects (57) 57
diabetic macular edema (56) 56
angiogenesis (55) 55
medicine & public health (55) 55
therapy (55) 55
care and treatment (53) 53
prospective studies (52) 52
genetic structures (51) 51
macular degeneration - complications (51) 51
aflibercept (50) 50
anti-vegf (50) 50
antibodies, monoclonal - administration & dosage (50) 50
intravitreal injection (48) 48
triamcinolone (48) 48
follow-up studies (46) 46
macular edema - drug therapy (46) 46
research (46) 46
visual acuity - physiology (46) 46
aptamers, nucleotide - administration & dosage (45) 45
intravitreal bevacizumab (45) 45
diabetic retinopathy - drug therapy (44) 44
choroidal neovascularization - etiology (43) 43
degeneration (43) 43
aptamers, nucleotide - adverse effects (42) 42
safety (42) 42
drug therapy (41) 41
subfoveal choroidal neovascularization (41) 41
triamcinolone acetonide (41) 41
bevacizumab avastin (40) 40
avastin (39) 39
optical coherence tomography (39) 39
edema (37) 37
intravitreal bevacizumab avastin (37) 37
visual acuity - drug effects (37) 37
analysis (36) 36
dosage and administration (36) 36
macular degeneration - physiopathology (36) 36
glaucoma (35) 35
intraocular pressure - drug effects (35) 35
retina (35) 35
retinopathy (35) 35
age related macular degeneration (34) 34
intraocular pressure (34) 34
sense organs (34) 34
wet macular degeneration - drug therapy (34) 34
antibodies, monoclonal - adverse effects (32) 32
laser photocoagulation (31) 31
adult (30) 30
antibodies, monoclonal, humanized - therapeutic use (30) 30
diabetes (30) 30
macular edema (30) 30
risk factors (30) 30
cancer (29) 29
intellectual property (28) 28
angiogenesis inhibitors (27) 27
clinical trials (27) 27
trial (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (577) 577
German (40) 40
French (10) 10
Turkish (8) 8
Spanish (4) 4
Czech (3) 3
Polish (3) 3
Russian (3) 3
Portuguese (2) 2
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CURRENT PHARMACEUTICAL DESIGN, ISSN 1381-6128, 2018, Volume 24, Issue 41, pp. 4853 - 4859
Journal Article
Early Human Development, ISSN 0378-3782, 2012, Volume 88, Issue 12, pp. 937 - 941
Abstract ROP remains a major cause of childhood blindness worldwide. The smallest, sickest infants develop the most severe forms of zone 1 ROP. Such eyes may... 
Advanced Basic Science | Neonatal and Perinatal Medicine | Retinopathy of prematurity (ROP) | Vascular endothelial growth factor inhibitors (anti-VEGF) | “”[pegaptanib, ranibizumab, bevacizumab, aflibercept] | Near confluent laser therapy | Intravitreal injections | ""[pegaptanib, ranibizumab, bevacizumab, aflibercept] | TRIAL | THERAPY | ZONE | INTRAVITREOUS BEVACIZUMAB | INFANTS | PEDIATRICS | Vascular endothelial growth factor inhibitors (anti-VEGF) [pegaptanib, ranibizumab, bevacizumab, aflibercept] | OBSTETRICS & GYNECOLOGY | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Vascular Endothelial Growth Factors - antagonists & inhibitors | Humans | Recombinant Fusion Proteins - therapeutic use | Aptamers, Nucleotide - therapeutic use | Infant | Aptamers, Nucleotide - adverse effects | Retinopathy of Prematurity - physiopathology | Bevacizumab | Retinopathy of Prematurity - diagnosis | Retinopathy of Prematurity - drug therapy | Infant, Premature | Ranibizumab | Receptors, Vascular Endothelial Growth Factor - adverse effects | Infant, Newborn | Care and treatment | Retrolental fibroplasia | Infants (Premature) | Lasers in surgery | Ophthalmology | Neovascularization | Vascular endothelial growth factor | Index Medicus
Journal Article
Ophthalmology, ISSN 0161-6420, 01/2019, Volume 126, Issue 1, pp. 55 - 63
Purpose: To review the evidence on the safety and efficacy of anti-vascular endothelial growth factor (VEGF) therapies for the treatment of neovascular... 
VEGF-TRAP | TRIALS | COST-EFFECTIVENESS | BEVACIZUMAB | PEGAPTANIB | WET | OPHTHALMOLOGY | VERTEPORFIN PHOTODYNAMIC THERAPY | INTRAOCULAR-PRESSURE | CHOROIDAL NEOVASCULARIZATION | RANIBIZUMAB
Journal Article
Retina, ISSN 0275-004X, 04/2011, Volume 31, Issue 4, pp. 662 - 668
Purpose: To assess the rate of infectious endophthalmitis and to describe the clinical and microbiological features of eyes that develop clinically suspected... 
VERTEPORFIN | INJECTION | SAFETY | bevacizumab | OPHTHALMOLOGY | MACULAR DEGENERATION | endophthalmitis | intravitreal injection | anti-vascular endothelial growth factor | pegaptanib | age-related macular degeneration | ranibizumab
Journal Article
Nature Communications, ISSN 2041-1723, 02/2017, Volume 8, Issue 1, pp. 14252 - 14252
Novel therapeutics are required for improving the management of chronic inflammatory diseases. Aptamers are single-stranded RNA or DNA molecules that have... 
AUTOANTIBODIES | NEUTROPHIL EXTRACELLULAR TRAPS | SYSTEMIC-LUPUS-ERYTHEMATOSUS | THERAPY | MACROPHAGES | PEGAPTANIB | MULTIDISCIPLINARY SCIENCES | JUVENILE RHEUMATOID-ARTHRITIS | DISEASE | ANTI-VEGF APTAMER | ONCOPROTEIN DEK | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 2010, Volume 5, Issue 12, pp. e15004 - e15004
Journal Article
NUCLEIC ACIDS RESEARCH, ISSN 0305-1048, 11/2010, Volume 38, Issue 21, pp. 7822 - 7829
Aptamers are short single-stranded nucleic acids with high affinity to target molecules and are applicable to therapeutics and diagnostics. Regardless of an... 
SYSTEM | CRYSTALLIZATION | REFINEMENT | PROTEIN-A | CAP-DEPENDENT TRANSLATION | PEGAPTANIB | BIOCHEMISTRY & MOLECULAR BIOLOGY | PURIFICATION | MOLECULAR MIMICRY | FC FRAGMENT | SELECTION
Journal Article
Ophthalmology, ISSN 0161-6420, 2008, Volume 115, Issue 10, pp. 1837 - 1846
Objective To examine the evidence about the safety and efficacy of anti–vascular endothelial growth factor (VEGF) pharmacotherapies for the treatment of... 
Ophthalmology | INTRAVITREAL BEVACIZUMAB AVASTIN | PIGMENT EPITHELIAL TEAR | PEGAPTANIB SODIUM | VISUAL HALLUCINATIONS | COHERENCE TOMOGRAPHY FINDINGS | RANIBIZUMAB LUCENTIS | OPHTHALMOLOGY | VERTEPORFIN PHOTODYNAMIC THERAPY | CONTROLLED CLINICAL-TRIALS | SUBGROUP ANALYSIS | CHOROIDAL NEOVASCULARIZATION SECONDARY
Journal Article
Journal Article
Ophthalmology, ISSN 0161-6420, 2006, Volume 113, Issue 10, pp. 1695 - 1705.e6
Journal Article
EUROPEAN JOURNAL OF OPHTHALMOLOGY, ISSN 1120-6721, 07/2019, Volume 29, Issue 4, pp. 361 - 367
Purpose: The aim of this study was to assess the effect of vitreous reflux and its amount on short-term intraocular pressure after intravitreal injection of... 
DRUG | intravitreal ranibizumab injection | NEED | POSTINJECTION REFLUX | PEGAPTANIB | vitreous reflux | VOLUME | ELEVATION | OPHTHALMOLOGY | TRIAMCINOLONE | LUCENTIS | Intraocular pressure
Journal Article
JOURNAL OF OPHTHALMOLOGY, ISSN 2090-004X, 2019, Volume 2019, pp. 1 - 6
Purpose. To present a cohort of treatment-naive patients with the neovascular form of age-related macular degeneration (nAMD) treated with aflibercept in a... 
MEDICINE, RESEARCH & EXPERIMENTAL | TACHYPHYLAXIS | EYES | PEGAPTANIB | OPHTHALMOLOGY | VEGF TRAP | OUTCOMES | RANIBIZUMAB
Journal Article
Experimental and Therapeutic Medicine, ISSN 1792-0981, 12/2017, Volume 14, Issue 6, pp. 6002 - 6006
The aim of the present study was to report the importance of pegaptanib sodium (PGSD) injection treatment for vascular active vitreoretinopathy (VAVR). A total... 
Vascular active vitreoretinopathy | Visual acuity | Inflammation | Pegaptanib sodium | SURGERY | MEDICINE, RESEARCH & EXPERIMENTAL | vascular active vitreoretinopathy | visual acuity | MACUGEN | MACULAR DEGENERATION | pegaptanib sodium | LOCUS | TRACTION | THERAPY | inflammation | DISEASE | PROLIFERATIVE VITREORETINOPATHY | FAMILIAL EXUDATIVE VITREORETINOPATHY
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, pp. CD007419 - CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | Quality of Life | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Index Medicus
Journal Article